-
Arena Pharma Could Be Developing Several Best-In-Class Agents
Friday, May 19, 2017 - 2:59pm | 370Read More...Leerink initiated coverage of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) with an Outperform rating and a $5 price target. New Management As A Catalyst For Growth Leerink analyst Joseph Schwartz noted several opportunities could create a significant amount of shareholder value, including the...
-
Bad Earnings Weigh In On Diet Stocks
Friday, February 14, 2014 - 1:22pm | 700Read More...Weight Watchers International (NYSE: WTW) shares are in a freefall Friday after missing Q4 EPS by $0.07 and slashing FY2014 guidance from $2.73 to $1.30-$1.60. In Friday’s trading, Weight Watchers is off by 26 percent at $22.65. This is the lowest level for the issue since April 23, 2009, when...
-
Top Trending Tickers On StockTwits For February 14
Friday, February 14, 2014 - 12:06pm | 902Read More...Here's a look at the top tickers trending on StockTwits.com Tesla: Robust sales in California According to Bloomberg, Tesla Motors' (NASDAQ: TSLA) Model S sedan ranks third place among luxury cars in California in 2013. According to a market report from the California New Car Dealers...
-
Market Wrap For February 10: Markets Cautious Ahead Of Yellen Testimony
Monday, February 10, 2014 - 5:47pm | 3302Read More...U.S. stocks traded mixed today as investors are anxiously waiting for Tuesday's testimony from Janet Yellen. Yellen will make her first appearance before the U.S. House of Representatives with a Senate session scheduled for Thursday. Elliot Spar, market strategist at Stifel told CNBC that "...
-
Wednesday Market Movers
Wednesday, July 18, 2012 - 12:31pm | 442Read More...VIVUS Inc. (NASDAQ: VVUS): VIVUS Inc., a biopharmaceutical company, announced on Tuesday that the FDA approved its new weight loss drug Qsymia. There is a large market for weight loss drugs because of the pervasiveness of obesity in the United States. In late June, the FDA approved another weight...
-
Jefferies Comments on VIVUS' Qnexa Ahead of FDA Approval
Friday, July 13, 2012 - 8:56am | 174Read More...Jefferies & Company has published a research report on VIVUS (NASDAQ: VVUS) commenting on the company's Qnexa approval ahead the July 17 decision by the FDA. In the report, Jefferies wrote, "We consider heart rate (HR) elevations to be the remaining critical issue for Qnexa approval by July 17...
-
JP Morgan Upgrades Orexigen Therapeutics to Overweight
Thursday, June 28, 2012 - 2:23pm | 388Read More...Orexigen Therapeutics (NASDAQ: OREX) was upgraded from Neutral to Overweight with a $10 price target by J.P. Morgan on Thursday following FDA approval of the drug Belviq (lorcaserin). Arena Pharmaceuticals (NASDAQ: ARNA) scored a big hit this week after this decision to approve the obesity drug...
